Tech Center 1600 • Art Units: 1625
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18111350 | RESPONSE-GUIDED HCV THERAPY | Non-Final OA | Emory University |
| 17787964 | METHOD FOR PRODUCING SOLID ELECTROLYTE | Final Rejection | IDEMITSU KOSAN CO.,LTD. |
| 18562107 | SOTORASIB DOSING REGIMEN | Non-Final OA | AMGEN INC. |
| 18543789 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Final Rejection | Mind Medicine, Inc. |
| 18362386 | DINUCLEAR PHOSPHANE GOLD(I) COMPLEXES FOR TREATING CANCER | Non-Final OA | Imam Abdulrahman Bin Faisal University |
| 18590606 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | Non-Final OA | Hoffmann-La Roche Inc. |
| 17780127 | PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18143391 | ORAL PRODUCTS WITH REDUCED IRRITATION | Final Rejection | NICOVENTURES TRADING LIMITED |
| 17836814 | ORAL PRODUCTS WITH REDUCED IRRITATION | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 18671931 | USE OF REBOXETINE TO TREAT NARCOLEPSY | Final Rejection | AXSOME THERAPEUTICS, INC. |
| 17794003 | MECHANOCHEMICAL SNAr REACTIONS | Non-Final OA | nChain Licensing AG |
| 18255749 | OIL-IN-WATER EMULSIFIED COMPOSITION | Final Rejection | KAO CORPORATION |
| 17776922 | METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE | Non-Final OA | YALE UNIVERSITY |
| 17913259 | CENTRAL NERVOUS SYSTEM POTENTIATING COMPOSITION | Non-Final OA | SHIBAURA INSTITUTE OF TECHNOLOGY |
| 18248535 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | Final Rejection | Bayer Aktiengesellschaft |
| 18763741 | THERAPEUTIC CONJUGATES | Non-Final OA | Totus Medicines Inc. |
| 18455378 | ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERS | Non-Final OA | Curio IP, LLC |
| 17760181 | Agent For Treating Or Preventing Pancreatic Fistula | Final Rejection | NOF CORPORATION |
| 17800049 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Final Rejection | Givaudan SA |
| 18267185 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 18025665 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | Non-Final OA | The Governing Council of the University of Toronto |
| 17772727 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | Final Rejection | Spiral Therapeutics Inc |
| 18327103 | PAIN-RELIEVING TOPICAL COMPOSITIONS | Non-Final OA | INNOCAN PHARMA LTD. |
| 18307905 | N-ACRYLOYLINDOLES AND METHODS OF USE | Non-Final OA | Versitech Limited |
| 18252882 | NOVEL PROCESS FOR THE PREPARATION OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE OR ITS SALTS THEREOF | Non-Final OA | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER |
| 17579541 | FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | Non-Final OA | Sage Therapeutics, Inc. |
| 18273299 | BIOCIDAL MIXTURES | Non-Final OA | LANXESS Deutschland GmbH |
| 17915361 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Non-Final OA | NIPPON CHEMIPHAR CO., LTD. |
| 18202567 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | Non-Final OA | Ojai Energetics PBC |
| 18546800 | HEMI-CITRATE SALTS OF GABA-A POSITIVE ALLOSTERIC MODULATOR AND CRYSTALLINE FORM THEREOF | Non-Final OA | Praxis Precision Medicines, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy